Bradykinin Research: What 22,857 Studies Show (2026) | RetatrutideCompare

Bradykinin — 22,857 studies indexed on PubMed. Activates B1 (induced by inflammation) and B2 (constitutive) receptors — vasodilation, increased vascular permeability, pain. Half-life: ~17 seconds. FDA status: Native not approved; antagonists are.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Bradykinin?

There are approximately 22,857 studies indexed on PubMed that mention Bradykinin (BK), based on a search last updated 2026-06-18.

Is Bradykinin FDA-approved?

FDA status: Native not approved; antagonists are.

How does Bradykinin work?

Activates B1 (induced by inflammation) and B2 (constitutive) receptors — vasodilation, increased vascular permeability, pain.

Reference facts

Also known as: BK
Category: Neuropeptide & Other
Mechanism of action: Activates B1 (induced by inflammation) and B2 (constitutive) receptors — vasodilation, increased vascular permeability, pain.
Targets: B1R, B2R
Indications under research or approved: Research target (Icatibant, a B2 antagonist, treats hereditary angioedema)
Regulatory status (reference entry): Native not approved; antagonists are
Half-life: ~17 seconds
Sequence: RPPGFSPFR
Sequence notes: Nonapeptide cleaved by kallikreins from kininogen.
Molecular weight (Da): 1060
First reported: 1949

Primary References

Marceau & Regoli, Nat Rev Drug Discov 2004 (Kinins)

Explore research articles about Bradykinin

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.